Gyre Therapeutics, Inc. (GYRE) P/E Ratio History
Historical price-to-earnings valuation from 2007 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Gyre Therapeutics, Inc. (GYRE) trades at a price-to-earnings ratio of 164.8x, with a stock price of $8.24 and trailing twelve-month earnings per share of $0.06.
The current P/E is 55% below its 5-year average of 365.3x. Over the past five years, GYRE's P/E has ranged from a low of 46.8x to a high of 1078.8x, placing the current valuation at the 36th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, GYRE trades at a 596% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, GYRE commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GYRE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Immunology and Inflammation Therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ARGXargenx SE | $47B | 60.0 | -Best | +348% |
TGTXTG Therapeutics, Inc. | $5B | 200.6 | -Best | +76% |
KNSAKiniksa Pharmaceuticals, Ltd. | $3B | 59.3 | -Best | +225% |
APLSApellis Pharmaceuticals, Inc. | $3B | 116.4 | -Best | +111% |
GLPGGalapagos N.V. | $2B | 5.9Lowest | -Best | +333% |
AUPHAurinia Pharmaceuticals Inc. | $2B | 6.8 | -Best | +5167%Best |
GYREGyre Therapeutics, Inc. | $711M | 164.8 | -Best | +104% |
RIGLRigel Pharmaceuticals, Inc. | $615M | 35.1 | -Best | +169% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $7.46 | $0.08 | 97.5x | -73% | |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $7.20 | $0.15 | 46.8x | -87% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $5.25 | $0.05 | 111.5x | -69% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $3.15 | $0.04 | 73.3x | -80% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $7.95 | $0.05 | 171.3x | -53% |
| FY2011 Q2 | $33185.25 | $36.23 | 916.0x | +151% | |
| FY2011 Q1 | $41879.25 | $57.59 | 727.2x | +99% | |
| FY2010 Q4 | Fri Dec 31 2010 00:00:00 GM | $41737.50 | $38.69 | 1078.8x | +195% |
| FY2007 Q3 | Sun Sep 30 2007 00:00:00 GM | $14159.25 | $42.13 | 336.1x | -8% |
| FY2007 Q2 | Sat Jun 30 2007 00:00:00 GM | $14411.25 | $53.92 | 267.3x | -27% |
| FY2007 Q1 | Sat Mar 31 2007 00:00:00 GM | $13104.00 | $68.15 | 192.3x | -47% |
Average P/E for displayed period: 365.3x
See GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GYRE vs AGIO
See how GYRE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GYRE stock overvalued or undervalued?
GYRE trades at 164.8x P/E, below its 5-year average of 365.3x. At the 36th percentile of historical range, the stock is priced at a discount to its own history.
How does GYRE's valuation compare to peers?
Gyre Therapeutics, Inc. P/E of 164.8x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is GYRE's PEG ratio?
GYRE PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2007-2025.